Reversibility of Neuropsychiatric Adverse Events after Switching to Darunavir/Cobicistat or Doravirine in Men on INSTI-Based Regimen
Authors:
- José Antonio Mata-MarínJMJosé Antonio Mata-Marín
- Carina Aurora Juárez-ContrerasCJCarina Aurora Juárez-Contreras
- Mara Soraya Rodríguez-EvaristoMRMara Soraya Rodríguez-Evaristo
- Olivia Concepción Martínez-CarrizalesOMOlivia Concepción Martínez-Carrizales
- Ericka Pompa-MeraEricka Pompa-Mera
- Alberto Chaparro SánchezASAlberto Chaparro Sánchez
- Salma Triana-GonzálezSTSalma Triana-González
- Ana Luz Cano-DíazACAna Luz Cano-Díaz
- Jesús Enrique Gaytán-MartínezJGJesús Enrique Gaytán-Martínez
Open Access
Abstract
Integrase strand transfer inhibitors (INSTI) are associated with neuropsychiatric adverse events (NPAEs). The aim of this study was to evaluate improvements in NPAEs after switching an INSTI-based regimen to darunavir/cobicistat (DRV/c) or doravirine (DOR). Methods: A prospective cohort study was conducted to evaluate the reversibility of NPAEs via the Patient Health Questionnaire (PHQ-9), the Insomnia Severity Index (ISI), and the Hospital Anxiety and Depression Scale (HADS-A and D) in patients who started antiretroviral therapy with dolutegravir (DTG) or bictegravir (BIC). These patients were switched to DRV/c or DOR. Scales were compared at the moment of the switch and 12 weeks later. Results: We included 1153 treatment-naïve men, 676 (58.7%) with BIC and 477 (41.3%) with DTG. A total of 32 (2.7%) experienced NPAEs that led to discontinuation. Insomnia was found in 20 patients; depression via PHQ-9 in 21 patients, via HADS-D in 5 patients, and anxiety via HADS-A in 12 patients. All of them were evaluated by a psychiatrist at the moment of the symptoms; 7 (21.8%) started psychotropic drugs. After 12 weeks of follow-up, PHQ-9, ISI, HADS-A, and HADS-D decreased, with a p-value ≤ 0.05. Conclusions: NPAEs seem to improve after switching to a DRV/c- or DOR-based regimen after the first 4 and 12 weeks.Keywords
This publication has 31 references indexed in Scilit:
- Sleep disturbances in HIV infection and their biological basisSleep Medicine Reviews, 2022
- Sleep Disorders in Human Immunodeficiency Virus: A Substudy of the Pharmacokinetics and Clinical Observations in People Over Fifty (POPPY) StudyOpen Forum Infectious Diseases, 2020
- Anxiety and depression among HIV patients of the infectious disease department of Conakry University Hospital in 2018Epidemiology and Infection, 2020
- Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohortJournal of Antimicrobial Chemotherapy, 2018
- Mind Matters: Treatment Concerns Predict the Emergence of Antiretroviral Therapy Side Effects in People with HIVAIDS and Behavior, 2018
- Sleep and neuropsychological performance in HIV+ subjects on efavirenz-based therapy and response to switch in therapyHIV Research & Clinical Practice, 2018
- Validity of the patient health questionnaire-9 to screen for depression in a high-HIV burden primary healthcare clinic in Johannesburg, South AfricaJournal of Affective Disorders, 2014
- Analyzing Sleep Abnormalities in HIV‐Infected Patients Treated with EfavirenzClinical Infectious Diseases, 2004
- Fluoxetine versus other types of pharmacotherapy for depression2003
- Screening Clinical Depression in HIV-Seropositive Patients Using the Hospital Anxiety and Depression ScaleAIDS and Behavior, 1999